Background: By acting on multiple targets and promoting diverse actions, angiotensin II (Ang II) plays a pivotal role in vascular function. Recent studies suggested that phosphodiesterase-5 (PDE-5) inhibitors exhibit therapeutic effects in cardiovascular diseases. Here, the effects of sildenafil on vascular disturbances were analyzed in a mouse model of Ang II-induced hypertension.
Methods and Results: Male C57BL/6 mice were used as untreated animals (control) or infused with Ang II (1000 ηg/kg/min) for 28 days and treated with sildenafil (40 mg/kg/min) or vehicle (Ang II) during the last two weeks. After 4 weeks, the Ang II animals exhibited a high systolic blood pressure (186±3 mmHg vs. 127±3 mmHg for control mice), which was attenuated by sildenafil (163±7 mmHg). The mesenteric vessels from the Ang II animals revealed damage to the endothelial layer, an increase in the cross-section area (1.9-fold) and vascular cell production of peroxynitrite (512±13 a.u.), which was ameliorated in the Ang II-Sil group (1.2-fold and 400±17 a.u.). Analysis of the vascular responsiveness showed an increased contractility response to norepinephrine in Ang II animals (Rmax: 70%), which was abolished by sildenafil through increased nitric oxide (NO) bioavailability and decreased reactive oxygen species (ROS) and vasoconstrictor prostanoids.
Conclusion: Sildenafil attenuates the morphofunctional deleterious effects of Ang II on resistance vessels. The benefits of sildenafil seem to occur through restoring the balance of ROS/NO/eicosanoids. Therefore, this study opened new avenues for further clinical targeting of the treatment of cardiovascular diseases related to activation of the renin-angiotensin system.
Keywords: Angiotensin, sildenafil, phosphodiesterase, ROS, nitric oxide, NADPH oxidase.
Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Risk Assessment of Obstructive Sleep Apnea and its Association with Fatigue and Sleepiness Among Hospital Inpatients
Current Respiratory Medicine Reviews Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Predictors of “Worsening Renal Function” in Patients Hospitalized in Internal Medicine Department
Current Drug Safety The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia
Current Pharmaceutical Biotechnology Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Adipocytokines in Non-functional Adrenal Incidentalomas and Relation with Insulin Resistance Parameters
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Atherosclerotic Molecules Targeting Oxidative Stress and Inflammation
Current Pharmaceutical Design Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Epistatic Control of Human Obesity as Revealed by Linkage Disequili-brium Mapping: A Report from the NHLBI-Sponsored WISE Study
Current Genomics Tissue Factor and Hypertension
Current Hypertension Reviews L-Type Calcium Channels
Current Pharmaceutical Design Pharmacological Treatment of Hypertension: Effects in Endothelial Function
Current Hypertension Reviews Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Hydroxamic Acids as Pharmacological Agents
Current Medicinal Chemistry Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety